Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BLESS fluctuates by 40.1% within 24 hours: Market panic continues after team sell-off

BLESS fluctuates by 40.1% within 24 hours: Market panic continues after team sell-off

Bitget PulseBitget Pulse2026/04/18 18:28
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, the price of BLESS rebounded from a low of $0.0060495 to a high of $0.0084763, currently quoting at $0.0060716, with a swing amplitude of 40.1%. The 24-hour trading volume ranged from approximately $9.68 million to $10.89 million, indicating active liquidity but overall pressure.

Brief Analysis of the Abnormal Move

- On-chain data shows that on April 16, the project team’s associated address sold about 300 million BLESS tokens (worth approximately $3.83 million), with 200 million deposited into Bitget exchange and 50 million bridged to BSC and swapped for USDT, directly causing the price to crash by 55%. The current 24-hour high-low volatility is the aftermath of the panic sell-off.

- No new official announcements or major on-chain events in the past 24 hours; volatility is primarily driven by liquidity shock from the prior sell-off and trader stop-loss/bottom-fishing dynamics.

Market Views and Outlook

Market sentiment is mostly negative, with the community concerned about team selling eroding trust. Although trading volume is high, much of it appears to be short covering; analysts warn that short-term risks remain high, with a possible further test of the $0.006 support. Caution is advised for further unlocked sell pressure, and recovery depends on platform beta developments and absence of new sell orders.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23